• Language
  • Transcriptome Sequencing
  • Eukaryote
  • mRNA Sequencing
  • Non-coding RNA Sequencing
  • Long non-coding RNA Sequencing
  • Small RNA Sequencing
  • Circular RNA Sequencing
  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics
  • Whole Genome Bisulfite Sequencing (Gene Methylation)
  • Reduced Representation Bisulfite Sequencing (RRBS-Gene Methylation)
  • ChIP-Seq
  • RIP-Seq
  • Metagenomics
  • 16S/18S/ITS Amplicon Metagenomic Sequencing
  • Shotgun Metagenomic Sequencing
  • Pre-made Library Sequencing
  • Pre-made Library Sequencing
  • Clinical Diagnostics
  • Clinical Whole Exome Sequencing (CLIA/CAP)
  • Clinical Panels
  • Genetic Testing
  • Oncology
  • NovoPM™ 2.0
  • NovoFocus™ NSCLC 2.0
  • NovoFocus™ CRC 2.0
  • NovoFocus™ PARPi CDx 1.0
  • NovoFocus™ CR
  • Cancer Immunotherapy Biomarkers
  • Patient's Case Study
  • Biopharma Services
  • Discovery and Pre Clinical
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • RNA-Seq
  • FFPE RNA-seq
  • Small RNA Sequencing
  • Pacbio Sequencing (DNA)
  • Pacbio Sequencing (RNA)
  • Pre-made Library Sequencing
  • Translational and Clinical
  • NovoPM™ 2.0
  • NovoNeoantigen™ 2.0
  • Star Allele Analysis
  • Tumor Microenvironment Analysis
  • Companion Diagnostics
  • Service Support
  • Service Workflow
  • Sample Preparation Guide
  • Sample Requirements
  • Quality Management
  • Data Analysis
  • FAQs​​
  • Technology
  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Resources
  • Publications
  • Downloads
  • Webinar
  • About
  • About Us
  • Major Milestones
  • Careers
  • News & Events
  • Partnership
  • Contact Us
  • De novo Sequencing
  • Animal & Plant De novo Sequencing
  • Microbial De novo Sequencing
  • Transcriptome Sequencing

  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics

    Metagenomics

    Pre-made Library Sequencing

  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Publications
  • Downloads
  • Webinar
  • About Us
  • Major Milestones
  • Careers
  • News & Events
  • Partnership
  • Tell us about your project
    Contact us to discuss how we can help you achieve your research goals
    Research Services

    Circular RNA Sequencing

    Overview

    Circular RNA (circRNA) molecules are a novel type of non-coding transcripts that is equipped with covalently cloesed loop lacking 5’end caps and 3’ poly(A) tails. The stable structure enables the circular transcripts resistant to the exonuclease digestion and provides mechanism for library construction with linear transcripts digested by RNase R. Novogene circRNA sequencing service (circRNA-seq) supports investigation on miRNA sponges and fulfills the regulatory function in gene expression.

    Service Specifications

    Applications

  • Expression Quantification of circRNA transcripts
  • Cellular function verification and animal mode test, such as cell proliferation and apoptosis
  • Function Verification, such as gene knockout, over-expression of circRNA genes
  • Competing endogenous RNA (ceRNA) investigation
  • Advantages

  • Extensive experience with numerical samples being successfully sequenced.
  • Unsurpassed data quality with a guaranteed Q30 score ≥ 80% that exceeds Illumina’s official benchmarks.
  • Comprehensive analysis using mainstream software and mature in-house pipeline to meet multiple bioinformatic requests.
  • Sample Requirements

    Library Type
    Sample Type
    Amount
    RNA Integrity Number
    (Agilent 2100)
    Purity
    (NanoDrop)
    circRNA Library
    Total RNA
    ≥ 5 μg
    Animal ≥ 7, Plant ≥ 6.5, with smooth baseline
    OD260/280 = 1.8-2.2;
    OD260/230 ≥ 1.8;
    lncRNA Library
    Total RNA
    ≥ 2 μg
    Animal ≥ 6.5, Plant ≥ 6, with smooth baseline

    Sequencing Parameters and Analysis Contents

    Platform Type
    Illumina Novaseq 6000
    Read Length
    Paired-end 150
    Recommended Sequencing Depth
    ≥ 40 million read pair per sample
    Standard Data Analysis
  • Data Quality Control
  • circRNA Identification
  • Transcript Expression Quantification & Differential Expression Analysis
  • Functional Enrichment Analysis
  • CircRNA Target Gene Prediction
  • Note: For detailed information, please refer to the Service Specifications and contact us for customized requests.

    Project Workflow

    Characterization of circRNA-Associated-ceRNA Networks in a Senescence-Accelerated Mouse Prone 8 Brain

    Background:

    Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases. Although many researchers have attempted to explain the origins of AD, developing an effective strategy in AD clinical therapy is difficult. Recent studies have revealed a potential link between AD and circRNA-associated-ceRNA networks. However, few genome-wide studies have identified the potential circRNA-associated-ceRNA pairs involved in AD.

    Sampling:

    total RNA extracted from the brain of senescence-accelerated mouse prone 8 (SAMP8) at the 7-month-old stage

    Sequencing Strategy:

    1. NEBNext® Multiplex Small RNA Library Prep Set for Illumina®, sequenced on an Illumina Hiseq 2500/2000 platform and 50bp single-end reads;
    2. NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina®, treated with RNase R, sequenced on an Illumina Hiseq 2500 platform and 125bp paired-end reads.

    Figure 1. Cluster Analysis Using a Heatmap

    Figure 2. circRNA-Associated-ceRNA Networks in SAMP8 Mice
    Conclusion:

    This research is the first to provide a systematic dissection of circRNA-associated-ceRNA profiling in SAMP8 mouse brain. The selected circRNA-associated-ceRNA networks can be potential biomarkers or therapeutic targets in AD and profoundly affect the clinical diagnosis, therapy, and prevention of AD in the future.

    Circular RNA expression profiles and bioinformatics analysis inovarian endometriosis

    Background:

    Circular RNAs (circRNAs) with miRNA response elements (MREs) could function as competing endogenous RNA (ceRNA) in regulating gene expression, thus playing vital roles in pathogenesis and progression of many diseases. However, the function of circRNAs in endometriosis remains unknown. This study was carried to profile the expression patterns of circRNAs in ovarian endometriosis.

    Sampling:

    total RNA extracted from six paired ectopic and eutopic endometrium tissues (ecEM vs. euEM)

    Sequencing Strategy:

    NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina®, sequenced on an Illumina Hiseq 4000 platform and 150 bp paired‐end reads.

    Figure. 3 CircRNA expression patterns in ecEM relative to those in euEM.

    Figure. 4 CircRNAs‐miRNAs‐mRNAs network.
    Conclusion:

    This study revealed that the circRNA expression profiles in ovarian endometriosis and differentially expressed circRNAs were obtained between paired ecEM and euEM. The ceRNA network and functional analysis of potential target genes highlighted the relationship between dysregulated circRNAs and ovarian endometriosis, which might be candidate factors for pathogenesis of this disease and be considered as promising therapeutic targets in the future.

    High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma

    Background:

    Liver cancer is the fourth leading cause of cancer associated deaths globally, of which the most common histological type is hepatocellular carcinoma (HCC). Nitidine chloride (NC) has been demonstrated to have an anticancer effect in HCC. However, the mechanism of action of NC against HCC remains largely unclear.

    Sampling:

    Total RNA extracted from three pairs of NC-treated and NC-untreated HCC xenograft tumor tissues.

    Sequencing Strategy:

    NEBNext® Ultra™ Directional RNA Library Prep Kit, sequenced on the HiSeq2000 platform by using 150 bp paired-end reads.

    Figure 5. Identification of circRNA-miRNA and miRNA-mRNA interactions.

    Figure 6. A circRNA-miRNA-mRNA regulatory network.
    Conclusion:

    In this study, we identified two circRNAs that could be potential therapeutic targets of NC in HCC and revealed the potential mode of action of the circRNA-miRNAmRNA network in HCC. Eighteen hubgenes associated with clinical outcomes of HCC patients were then identified. The findings, for the first time, provide novel insights into the potential of circRNAs as therapeutic targets of NC against HCC.


    Length Distribution of circRNA


    Quantification


    Differential Expression


    GO Enrichment


    KEGG Enrichment


    miRNA_Binding_Site